logo

DRMA

Dermata Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About DRMA

Dermata Therapeutics, Inc.

A clinical-stage biotech company focusing on the treatment of medical and aesthetic skin conditions

Pharmaceutical
Invalid Date
08/13/2021
NASDAQ Stock Exchange
8
12-31
Common stock
3525 Del Mar Heights Rd., #322, San Diego, CA 92130
--
Dermata Therapeutics, Inc., in Delaware in December 2014. They are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative drug candidates for the treatment of medical and aesthetic skin diseases and conditions, which the company believes represent a significant market opportunity due to the lack or non-existence of current therapies.

Company Financials

EPS

DRMA has released its 2023 Q3 earnings. EPS was reported at -0.54, versus the expected -0.63, beating expectations. The chart below visualizes how DRMA has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime